ValuEngine cut shares of AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) from a buy rating to a hold rating in a research note released on Tuesday, ValuEngine reports.

Separately, Zacks Investment Research cut AEterna Zentaris from a buy rating to a hold rating in a research note on Friday, March 22nd.

Shares of AEterna Zentaris stock opened at $2.11 on Tuesday. AEterna Zentaris has a 52-week low of $1.29 and a 52-week high of $5.57. The stock has a market capitalization of $33.54 million, a P/E ratio of 8.44 and a beta of 1.34.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.04 by ($0.18). AEterna Zentaris had a negative net margin of 666.76% and a negative return on equity of 328.95%. The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $4.20 million. On average, equities analysts anticipate that AEterna Zentaris will post 1.71 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in AEZS. AJO LP bought a new stake in AEterna Zentaris in the 1st quarter valued at about $1,031,000. Acadian Asset Management LLC raised its stake in AEterna Zentaris by 271.2% in the 1st quarter. Acadian Asset Management LLC now owns 167,222 shares of the biopharmaceutical company’s stock valued at $777,000 after acquiring an additional 122,173 shares during the period. Renaissance Technologies LLC raised its stake in AEterna Zentaris by 232.8% in the 1st quarter. Renaissance Technologies LLC now owns 110,078 shares of the biopharmaceutical company’s stock valued at $512,000 after acquiring an additional 77,000 shares during the period. Virtu Financial LLC bought a new stake in AEterna Zentaris in the 1st quarter valued at about $179,000. Finally, O Shaughnessy Asset Management LLC bought a new stake in AEterna Zentaris in the 4th quarter valued at about $66,000. Institutional investors and hedge funds own 13.67% of the company’s stock.

AEterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

Read More: Net Margin – Understanding the Different Kinds of Profit

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.